<p>Qualigen Therapeutics Inc. has announced new management changes effective November 17, 2025. Koti Meka has been appointed as Executive Director, bringing experience from his roles as Chief Financial Officer at Qualigen and Faraday Future, as well as previous positions at Ford Motor Company and Accenture. Jie Sheng has been named Chairman of the Board. Additionally, Chad Chen has joined the Board’s Audit Committee. Graydon Bensler and Braeden Lichti have resigned from the Board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qualigen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-024487), on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

QLGN

<p>Qualigen Therapeutics Inc. has announced management changes effective November 17, 2025. Koti Meka is appointed as Executive Director, and Jie Sheng as Chairman of the Board. Chad Chen joins the Board’s Audit Committee, while Graydon Bensler and Braeden Lichti resign from the Board. This information was published via EDGAR by Qualigen Therapeutics.</p>

Qualigen Therapeutics Appoints Koti Meka as Executive Director and Jie Sheng as Chairman